ClinicalTrials.gg
CompletedNCT01304134Updated Aug 11, 2015

Oxycodone Hydrochloride Injection in the Postoperative Pain Relieving Treatment

A Phase 3 interventional study of Oxycodone and Morphine in Other Acute Postoperative Pain, sponsored by Mundipharma (China) Pharmaceutical Co. Ltd. Completed at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2015-08-11.

Sponsored by Mundipharma (China) Pharmaceutical Co. Ltd (part of Mundipharma) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
240
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 32 studies testing oxycodone in Pain, Postoperative — 5 open to participants now, 7 under way, 1 of them phase 3. Oxycodone · Pain, Postoperative.

Enrollment
8th of 32
240 · median 126
Started
2010
the only one that year
Phase 3
4 of 32
1 open now
Registered
6th of 32
by date
Lead sponsor
2 of 32
Mundipharma (China) Pharmaceutical Co. Ltd

Among the 32 studies testing oxycodone in Pain, Postoperative, this one is the 8th largest by enrollment, is the only one that started in 2010, is one of 4 in phase 3, and was the 6th registered.

Pain, Postoperative

5,654 studies on the registry are indexed under Pain, Postoperative; 1,233 are open to participants now.

Browse Pain, Postoperative studies →

Open to participants now

5 of the 32 studies testing oxycodone in Pain, Postoperative are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About oxycodone

Oxycodone: first FDA approval 1950 (PERCODAN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 676 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 327 (48%) stop at 75 or younger; 74 take children under 18; 128 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies testing oxycodone in Pain, Postoperative, or all of them as a file.
02

Study summary

To determine the efficacy and safety of oxycodone i.v. patient-controlled analgesia (PCA) in the pain relieving treatment during 48h postoperative period, by comparing with morphine i.v. PCA.

03

Conditions studied

  • Other Acute Postoperative Pain

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients of either sex aged 18 to 65 years old, with a standard body weight [standard body weight = height (cm) - 100] ±15%.
  2. and II.
  3. Scheduled on elective open upper abdominal surgery under general anesthesia (liver, gall bladder, spleen, stomach, kidney, colon surgery), of which predicted operation duration is between 2-4h.
  4. Hospitalized patients on non-emergency condition who have been given appropriate preoperative treatments.
  5. Patients who are willing to participate in the study and have signed the written .
  6. Negative pregnancy test result should be obtained for women of child-bearing age.

Exclusion criteria

Exclusion Criteria:

  1. Long-term analgesics or psychotropic drugs (including opioids, NSAIDs, sedatives, antidepressants) taken for the chronic pain, or patients abusing alcohol.
  2. Body weight is less than or over ±15% of the standard body weight.
  3. Severe impairment of liver and renal function at preoperative stage (, AST, BUN, Cr).
  4. Medical history of recovering from abnormal surgery anesthesia.
  5. Medical history of hypertension (Systolic blood pressure ≥180Hg, Diastolic blood pressure 110Hg).
  6. Esophagus reflux disease.
  7. Sedatives, anti-emetics, and anti-pruritic drugs were taken 24 hours before operation.
  8. Have known to opioids.
  9. Monoamine oxidase inhibitors and antidepressant drugs were taken within 15 days.
  10. Patients with shock.
  11. Patients with .
  12. Patients can not understand the VAS or unable to use PCA.
  13. Pregnant or parturient women.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
240 participants (actual)

Study arms

  • Experimental
    Oxycodone i.v.

    To determine the efficacy and safety of oxycodone i.v. patient-controlled analgesia (PCA)

    Drug: Oxycodone

  • Active comparator
    Morphine i.v.

    To determine the efficacy and safety of oxycodone i.v. patient-controlled analgesia (PCA)

    Drug: Morphine

Interventions

  • dosage:10mg/l dosage form:injection frequency:via PCA pump, background rate:0.5ml/h, 2ml/time duration:48 hours

    Also known as: Oxycodone Injection

  • dosage: 10mg/ml dosage form: injection frequency: via PCA pump, background rate: 0.5ml/h, 2ml/times duration: 48 hours

    Also known as: Morphine Injection

06

What researchers measure

Primary outcomes

  1. Measuring VAS

    Measuring resting and coughing VAS, assessing the intensity of pain

    Time frame: 3h post-operation

  2. Measuring VAS

    Measuring resting and coughing VAS, assessing the intensity of pain

    Time frame: 24 hours post operation

  3. Measuring VAS

    Measuring resting and coughing VAS, assessing the intensity of pain

    Time frame: 48 hours post operation

Secondary outcomes

  1. Dosage

    Total dosage of study drugs within 48h.

    Time frame: Within 48h

  2. The dosage of other rescue analgesic drugs used within 48h post-operation.

    The dosage of other rescue analgesic drugs used within 48h post-operation.

    Time frame: 48hrs

  3. The invalid times and the total times of PCA application

    The invalid times and the total times of PCA application

    Time frame: 48hrs

  4. Satisfaction degree for analgesia

    Satisfaction degree for analgesia after the treatment

    Time frame: 48hrs

  5. AE occurrence and abnormal lab value

    AE and normal lab value will be recorded during the study

    Time frame: 48hrs

07

Study locations

1 site
  • Investigational site
    Beijing, Beijing 100022, China
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2010, a primary completion of Aug 2010 and a completion of Aug 2010. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 23, 2011
First posted
Feb 25, 2011
Start
Mar 2010
Primary completionActual
Aug 2010
CompletionActual
Aug 2010
Last update
Aug 11, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 11, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01304134
Responsible party
Sponsor
First posted
Feb 25, 2011
Start date
Mar 2010
Primary completion
Aug 2010
Completion
Aug 2010
Last update
Aug 11, 2015

Study contacts

Mundipharma China Ltd.
study chair · Mundipharma China Ltd.
Mundipharma China Ltd.
principal investigator · Investigational Site Beijing, China

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Oxycodone

Start the discussion